日本医科大学武蔵小杉病院腫瘍内科,
Burger RA, et al. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of…
Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Overview of attention for article published in Journal of Clinical Oncology, March 2014
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
Good Attention Score compared to outputs of the same age and source (74th percentile)
Mentioned by
- policy
- 1 policy source
- 6 X users
- 1 weibo user
- 1 Facebook page
- guideline
- 3 clinical guideline sources
Readers on
- mendeley
- 89 Mendeley